KRAS and neoplasm: Additionally, to evaluate the effect of tumor suppression using TUS-007 in a subcutaneous xenograft model of SW620-luc human colon cells (homozygous KRAS G12V), tumor-bearing nude mice were administered TUS-007 (80 mg/kg), cetuximab (1 mg/body), or the vehicle control via intraperitoneal injection.